Here, we reviewed the recent literature regarding the clinical significance of the influenza virus infection ... hematopoietic stem-cell transplant (HSCT) recipients, and patients receiving ...
A timely medical intervention in the form of a bone marrow transplant, medically known as hematopoietic stem cell ...
Pharma major, Zydus Lifesciences on Wednesday said that it has launched ANVIMO (Letermovir), a new and innovative treatment ...
FDA has provided input on key elements of the SER-155 allo-HSCT clinical development plans including support for the proposed primary efficacy ...
WHO declared the start of the COVID-19 pandemic. Although patients with haematological malignancies have greatly benefited ...
designed to protect patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT) from infections, and other oral microbiome therapies in its pipeline. SER-155 is currently in the ...
Theoretically, HSCT offers 2 major advantages in the treatment ... During the first part of this phase, the major problems encountered are infections from endogenous bacteria, the reactivation ...
Traditional CMV treatments, such as ganciclovir and valganciclovir, have notable limitations, including toxicity and bone ...
Seres Therapeutics (MCRB) announced that it has received constructive feedback from a Type B Breakthrough Therapy designation engagement with ...
AlloHeme test accurately predicts relapse post-allo-HSCT in AML and MDS, with a median lead time of 36 days. The ACROBAT study involved 287 patients, showing significant predictive value of ...
Zydus Lifesciences announced that it has launch ANVIMO (Letermovir), a new and innovative treatment for the prevention of Cytomegalovirus (CMV) infection in hematopoietic stem cell transplant (HSCT) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback